Amgen Issues the Following Statement in Response to Erroneous News Coverage on Denosumab

There have been reports in the media containing incomplete and inaccurate speculation, including speculation on the rates of fracture in a pivotal denosumab trial. While Amgen issued a topline release on the pivotal study results on July 25, denosumab has not been approved for commercial use and full data from the pivotal study has not been disclosed; it will be presented September 16, 2008, at the American Society of Bone and Mineral Research (ASBMR) in Montreal. Moreover, the article contains speculation about price and any commentary about price is premature.